{"protocolSection": {"identificationModule": {"nctId": "NCT00642616", "orgStudyIdInfo": {"id": "MKC-TI-134"}, "organization": {"fullName": "Mannkind Corporation", "class": "INDUSTRY"}, "briefTitle": "Evaluate Safety of Technosphere\u00ae Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease", "officialTitle": "A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere\u00ae Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "TERMINATED", "whyStopped": "Terminated upon recommendation of the Data Safety Monitoring Board (DSMB)", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2014-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-21", "studyFirstSubmitQcDate": "2008-03-24", "studyFirstPostDateStruct": {"date": "2008-03-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-23", "resultsFirstSubmitQcDate": "2016-02-12", "resultsFirstPostDateStruct": {"date": "2016-02-15", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-06-09", "dispFirstSubmitQcDate": "2009-11-18", "dispFirstPostDateStruct": {"date": "2009-11-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-04-12", "lastUpdatePostDateStruct": {"date": "2017-04-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Mannkind Corporation", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function \\& pulmonary safety"}, "conditionsModule": {"conditions": ["Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus", "Moderate Chronic Obstructive Pulmonary Disease", "Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 34, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Technosphere\u00ae Insulin (Asthma)", "type": "EXPERIMENTAL", "description": "Technosphere\u00ae Insulin Inhalation Powder administered prandially in diabetic participants with Asthma", "interventionNames": ["Drug: Technosphere\u00ae Insulin"]}, {"label": "Usual Care (Asthma)", "type": "ACTIVE_COMPARATOR", "description": "Usual anti diabetic care in Diabetic participants with Asthma", "interventionNames": ["Drug: Usual Care"]}, {"label": "Technosphere\u00ae Insulin (COPD)", "type": "EXPERIMENTAL", "description": "Technosphere\u00ae Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)", "interventionNames": ["Drug: Technosphere\u00ae Insulin"]}, {"label": "Usual Care (COPD)", "type": "ACTIVE_COMPARATOR", "description": "Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)", "interventionNames": ["Drug: Usual Care"]}], "interventions": [{"type": "DRUG", "name": "Technosphere\u00ae Insulin", "description": "Technosphere\u00ae Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents", "armGroupLabels": ["Technosphere\u00ae Insulin (Asthma)", "Technosphere\u00ae Insulin (COPD)"], "otherNames": ["Afrezza"]}, {"type": "DRUG", "name": "Usual Care", "description": "Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin", "armGroupLabels": ["Usual Care (Asthma)", "Usual Care (COPD)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Post-bronchodilator FEV1 From Baseline to Week 52", "description": "Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.", "timeFrame": "52 Weeks"}], "secondaryOutcomes": [{"measure": "Number of Participants With Asthma Exacerbation by Treatment Arm", "description": "Number of participants who experienced worsening of asthma symptoms", "timeFrame": "Baseline to Week 52"}, {"measure": "Number of Participants With COPD Exacerbation by Treatment Arm", "description": "Number of participants who experienced worsening of COPD symptoms", "timeFrame": "Baseline to Week 52"}, {"measure": "Change in HbA1C From Baseline to Week 52", "timeFrame": "Baseline, week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nAsthma\n\n* Physician diagnosis of asthma with history of any or all of the following: recurrent wheezing, recurrent chest tightness, recurrent difficulty breathing, or cough, particularly worse at nighttime\n* Never smoked or former smokers (= 6 months since cessation)\n* \u226518 years of age\n* Prebronchodilator Forced Expiratory Volume in 1sec (FEV1) \u2265 60% Third National Health and Nutrition Examination Survey (NHANES III) predicted, prebronchodilator total lung capacity (TLC) \u2265 80% predicted Intermountain Thoracic Society (ITS), and prebronchodilator single breath carbon monoxide diffusing capacity of the lung (DLco) (unc) \u226570% predicted (Miller)\n* \\< 30% day-to-day variability in daily morning Peak expiratory Volume (PEF) during the 2-week run-in period\n* Significant improvement in pre- to postbronchodilator spirometry (defined as an increase from baseline of \u2265 12% and \u2265 200 mL in FEV1 or Forced Vital Capacity \\[FVC\\]) at Screening/Visit 1 or documented significant improvement in pre- to postbronchodilator spirometry (as defined above) within past 12 months in subject's medical records or a documented positive methacholine challenge test within the past 12 months\n\nCOPD\n\n* Physician diagnosis of COPD (including emphysema and/or chronic bronchitis), history of dyspnea and/or intermittent or daily chronic cough with or without sputum production, not attributable to any other known cause\n* Former smoker (\u2265 6 months since cessation) with smoking history of \u2265 10 pack years\n* \u226540 years of age\n* Postbronchodilator FEV1/FVC ratio \\< 70%\n* Postbronchodilator FEV1 \u2265 50% NHANES III predicted, total lung capacity (TLC) \u2265 80% predicted ITS, and DLco (unc) \u2265 50% predicted (Miller)\n\nBoth\n\n* Clinical diagnosis of Type1 or 2 diabetes mellitus for \u2265 12 months and no change in anti-diabetic regiment for at least 90-days prior to screening\n* BMI of, \\< 39 kg/m2\n* Urine cotinine level \u2264 100ng/dL\n* Clinical diagnosis of obstructive lung disease\n* HbA1C \\> 6.5% \u2264 11.5%\n\nExclusion Criteria:\n\n* History of pulmonary exacerbation within 8 weeks of screening/V1 or between V1 and V2\n* Use of systemic corticosteroids or antibiotics for respiratory illness within 8 weeks of screening/V1 OR between V1 and V2\n* Increase from baseline in the use of short-acting bronchodilator or short-acting anticholinergic agents, or the combination of the 2, by \u22656 puffs or \u22653 nebulizer treatments per day for \u2265 2 days\n* Treatment with supplemental oxygen therapy, room air oxygen saturation, 94% or history of intubation or ICU admission for respiratory illness in the past 5 yrs.\n* Greater than 2 hospitalizations or ER or urgent care visits or required \\>3 courses of systemic steroid in the past 12 months for respiratory illness\n* Use of Symlin\u00ae (pramlintide acetate) within the preceding 90 days\n* Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between Screening and Baseline\n* Previous exposure to any inhaled insulin product\n* Currently using an insulin delivery pump\n* Requires significant change (define as initiation of a new medication or change in the dose or frequency of the controller medications) in the asthma or COPD therapeutic regimen within 8 weeks of Screening/Visit 1 (Week -4) or between Visit 1 and Baseline/Visit 2\n* Severe complications of diabetes mellitus, in the opinion of the PI or sub-investigator, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy; nephropathy with renal failure, renal transplant and/or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene; and/or vascular claudication", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Chief Medical Officer", "affiliation": "Mannkind Corporation", "role": "STUDY_CHAIR"}], "locations": [{"city": "Mission Hills", "state": "California", "zip": "91345", "country": "United States", "geoPoint": {"lat": 34.68952, "lon": -120.4356}}, {"city": "San Diego", "state": "California", "zip": "92117", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"city": "Palm Harbor", "state": "Florida", "zip": "34684", "country": "United States", "geoPoint": {"lat": 28.07807, "lon": -82.76371}}, {"city": "Flint", "state": "Michigan", "zip": "48504", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"city": "Greenville", "state": "South Carolina", "zip": "29615", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"city": "Spartanburg", "state": "South Carolina", "zip": "29302", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"city": "Dallas", "state": "Texas", "zip": "75225", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"city": "Federal Way", "state": "Washington", "zip": "98003", "country": "United States", "geoPoint": {"lat": 47.32232, "lon": -122.31262}}, {"city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"city": "Yaroslavl", "state": "RUS", "zip": "150002", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"city": "Kemerovo", "state": "RU", "zip": "650066", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"city": "Moscow", "state": "RU", "zip": "105120", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"city": "St Petersburg", "state": "RU", "zip": "198013", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "St. Petersburg", "state": "RU", "zip": "191015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "St. Petersburg", "state": "RU", "zip": "191119", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "St. Petersburg", "state": "RU", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "Kiev", "state": "UA", "zip": "04114", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"city": "Kyiv", "state": "UA", "zip": "01021", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "2 week screening period followed by a 2 week run-in period. After the screening period, 51 participants were randomized and 34 participants met eligibility criteria after the 2 week run-in period and were treated . Study was terminated based on data safety monitoring board recommendations.", "recruitmentDetails": "A total of 517 participants were screened in 5 countries . First participant was screened in March 2009.", "groups": [{"id": "FG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Asthma"}, {"id": "FG001", "title": "Usual Care (Asthma)", "description": "Usual and anti diabetic care in diabetic participants with Asthma."}, {"id": "FG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)"}, {"id": "FG003", "title": "Usual Care (COPD)", "description": "Usual and anti diabetic care in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Study Terminated by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Subjects who received at least one dose of study medication", "groups": [{"id": "BG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic patients with Asthma"}, {"id": "BG001", "title": "Usual Care (Asthma)", "description": "Usual and anti diabetic care in diabetic participants with Asthma."}, {"id": "BG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic patients with COPD"}, {"id": "BG003", "title": "Usual Care (COPD)", "description": "Usual and anti diabetic care in diabetic participants with COPD."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "34"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "69.00", "spread": "7.26"}, {"groupId": "BG001", "value": "49.75", "spread": "15.73"}, {"groupId": "BG002", "value": "67.44", "spread": "8.38"}, {"groupId": "BG003", "value": "68.88", "spread": "8.20"}, {"groupId": "BG004", "value": "64.03", "spread": "12.71"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "13"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "21"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Post-bronchodilator FEV1 From Baseline to Week 52", "description": "Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.", "populationDescription": "Only two participants completed both time points (one in the Usual Care (Asthma) Arm and one in the Usual Care (COPD) Arm); data are not provided due to privacy concerns.", "reportingStatus": "POSTED", "timeFrame": "52 Weeks", "groups": [{"id": "OG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Asthma"}, {"id": "OG001", "title": "Usual Care (Asthma)", "description": "Usual and anti diabetic care in diabetic participants with Asthma."}, {"id": "OG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with COPD"}, {"id": "OG003", "title": "Usual Care (COPD)", "description": "Usual and anti diabetic care in diabetic participants with COPD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Asthma Exacerbation by Treatment Arm", "description": "Number of participants who experienced worsening of asthma symptoms", "populationDescription": "Safety population: Participants who received at least one dose of study medication. The outcome applies only to participants with underlying Asthma", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Asthma"}, {"id": "OG001", "title": "Usual Care With Anti-diabetic Agents (Asthma)", "description": "Usual anti diabetic care in diabetic participants with Asthma"}, {"id": "OG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with COPD"}, {"id": "OG003", "title": "Usual Care With Anti-diabetic Agents (COPD)", "description": "Usual anti diabetic care in diabetic participants with COPD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "8"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}], "classes": [{"title": "Exacerbation of Asthma", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "No Exacerbation of Asthma", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With COPD Exacerbation by Treatment Arm", "description": "Number of participants who experienced worsening of COPD symptoms", "populationDescription": "Safety population: Participants who received at least one dose of study medication. The outcome applies only to participants with underlying COPD", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Asthma"}, {"id": "OG001", "title": "Usual Care With Anti-diabetic Agents (Asthma)", "description": "Usual anti diabetic care in diabetic participants with Asthma"}, {"id": "OG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with COPD"}, {"id": "OG003", "title": "Usual Care With Anti-diabetic Agents (COPD)", "description": "Usual anti diabetic care in diabetic participants with COPD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "9"}, {"groupId": "OG003", "value": "8"}]}], "classes": [{"title": "COPD Exacerbation", "categories": [{"measurements": [{"groupId": "OG002", "value": "3"}, {"groupId": "OG003", "value": "1"}]}]}, {"title": "No Exacerbation", "categories": [{"measurements": [{"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "7"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1C From Baseline to Week 52", "populationDescription": "Only two participants completed both time points (one in the Usual Care (Asthma) Arm and one in the Usual Care (COPD) Arm); data are not provided due to privacy concerns", "reportingStatus": "POSTED", "timeFrame": "Baseline, week 52", "groups": [{"id": "OG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Asthma"}, {"id": "OG001", "title": "Usual Care (Asthma)", "description": "Usual and anti diabetic care in diabetic participants with Asthma."}, {"id": "OG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with COPD"}, {"id": "OG003", "title": "Usual Care (COPD)", "description": "Usual and anti diabetic care in diabetic participants with COPD"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "All Adverse Events (AE) were collected from signature of the informed consent form up to 30 days after the last study visit or study related procedure was performed regardless of seriousness or relationship to investigational product", "description": "Analysis was done on safety population", "eventGroups": [{"id": "EG000", "title": "Technosphere\u00ae Insulin (Asthma)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with Asthma", "seriousNumAffected": 2, "seriousNumAtRisk": 9, "otherNumAffected": 8, "otherNumAtRisk": 9}, {"id": "EG001", "title": "Usual Care With Anti-diabetic Agents (Asthma)", "description": "Usual anti diabetic care in diabetic participants with Asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 7, "otherNumAtRisk": 8}, {"id": "EG002", "title": "Technosphere\u00ae Insulin (COPD)", "description": "Technosphere\u00ae Insulin Inhalation Powder in combination with an antidiabetic regimen in diabetic participants with COPD", "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 4, "otherNumAtRisk": 9}, {"id": "EG003", "title": "Usual Care With Anti-diabetic Agents (COPD)", "description": "Usual anti diabetic care in diabetic participants with COPD", "seriousNumAffected": 0, "seriousNumAtRisk": 8, "otherNumAffected": 6, "otherNumAtRisk": 8}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 8}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hypercalcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "B-cell lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hypoglycemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 8}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hypoventilation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Muscle spasms", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Oropharyngeal spasm", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Respiratory tract infection viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Dyslipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hot flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pulmonary function test decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Pyelonephritis chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Tracheitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Type 1 Diabetes Mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Monocyte count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Productive cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 8}]}, {"term": "Bronchial obstruction", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Echymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Seasonal allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Venous insufficiency", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (15.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 9}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 8}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "- Early termination of trial leading to small numbers of subjects analyzed"}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "MannKind has right to 1st joint multicenter publication. After 1st publication PI may publish data only if PI submits proposed publication to MNKD for review 60 days prior to publication date. MNKD may remove any confidential information. If a multicenter publication is not submitted 12 months after conclusion, abandonment, or termination of the Study at all sites, or if MNKD confirms there will be no multicenter Study publication, PI may publish the Study results subject to MNKD rights herein."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "ContactUS@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Argentina", "Brazil", "Chile", "Germany", "Hungary", "Slovakia"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000029424", "term": "Pulmonary Disease, Chronic Obstructive"}, {"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Type 1 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11168", "name": "Lung Diseases", "asFound": "Pulmonary Disease", "relevance": "HIGH"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "asFound": "Obstructive Pulmonary Disease", "relevance": "HIGH"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "asFound": "Chronic Obstructive Pulmonary Disease", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M29800", "name": "Insulin, Short-Acting", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}